2010 DePuy Hip Recall

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The 2010 DePuy Hip Replacement Recall was instituted when DePuy Orthopaedics, Inc., a division of Johnson and Johnson, recalled its ASR XL Acetabular metal-on-metal hip replacement system on August 24, 2010.[1][2]

Background[edit]

The recall came after data from a study indicated that the five year failure rate of this product is approximately 13%, or 1 in 8 patients.[3] Even if the defective device is replaced, it can leave behind dangerous, possibly deadly fragments that may not be discovered for years. DePuy identified reasons for the failure of the hip replacement system as component loosening, component malalignment, infection, fracture of the bone, dislocation, metal sensitivity and pain. Additional complications from the hip replacement system may include increased metal ion levels in the blood, bone staining, necrosis, swelling, nerve damage, tissue damage and/or muscle damage.

At the beginning of 2010, DePuy Orthopaedics said they were phasing out the ASR Hip Implant because of declining sales, but never mentioned the high failure rate data from an Australian implant registry. In March 2010, the New York Times reported that DePuy issued its first warning to doctors and patients about the high early failure rate.[1] However, at this point, they still had not issued a recall of the product. In fact, they claimed any statements referencing a recall were false.[4]

Lawsuits[edit]

About 93,000 persons worldwide received an ASR implant.[5] The first lawsuit in the United States against DePuy Orthopaedics was filed on June 15, 2010. Shine Lawyers commenced an Australian class action in the Federal Court of Australia on September 27, 2011, against DePuy International Pty Ltd and Johnson and Johnson Medical Pty Ltd. Both lawsuits claimed that the DePuy ASR hip replacement was defectively designed, that DePuy knew that there were problems with the implant early on but didn't do anything to let patients or their surgeons know about the possible problems. The United States Judicial Panel on Multidistrict Litigation filed a ruling on December 7, 2010[6] that determined the fate of the thousands of lawsuits regarding DePuy Hip Recalls in the United States. Its ruling stated that all cases filed across the country, "are transferred to the Northern District of Ohio and, with the consent of that court, assigned to the Honorable David A. Katz for coordinated or consolidated pretrial proceedings."

On January 26, 2011, Judge Katz entered an order in the multidistrict litigation naming the leadership counsel for both the plaintiffs and the defendants. Ben Gordon, Eric Kennedy, Ellen Relkin, Mark Robinson, Christopher Seeger, and Steven Skikos were named on the plaintiffs' Executive Committee. Robert Tucker and Susan Sharko were named as defendants' Co-Lead Counsel. Discovery of documents from Johnson & Johnson and DePuy Orthopaedics has commenced.

In 2014, Johnson & Johnson announced it would not withdraw a $2.5 billion global settlement. Settlements began at a base of $250,000. Johnson & Johnson continued to deny culpability. [7]

On March 17, 2016, United States District Judge Ed Kinkeade, after receiving the juries verdict, signed final judgment for Case# MDL Docket No. 3:11-MD-2244-K. Jury awarded 5 plaintiffs (3:13-cv-1071, 3:14-cv-1994,3:12-cv-1672,3:11-cv-2800, & 3:11-cv-1941) a combined award of $120 million against DePuy Orthorpaedics Inc, and a combined award $240 million against Johnson & Johnson.§(United States District Court Northern District of Texas Dallas Division Web-Site)

India[edit]

Of the total number of people receiving the implants, about 4,700 were in India. As of 2018, J&J committed to working with the Indian government to support all Indian ASR patients. In late 2018, an Indian government report, the accuracy of which has been disputed by J&J, proposed that each patient who had a faulty implant should receive a lump sum payment of ₹2 million (US$27,812). J&J had previously provided US$2.25 million to cover diagnostic and surgical and diagnostic costs to patients with defective implants, but the Indian government was concerned that these monies included no compensatory funds.[5]

References[edit]

  1. ^ a b Barry Meier (March 9, 2010). "With Warning, a Hip Device Is Withdrawn". New York Times. Retrieved 2010-12-17. A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.
  2. ^ Barry Meier (December 15, 2010). "The Implants Loophole". New York Times. Retrieved 2010-12-17. A recently recalled artificial hip made by a unit of Johnson & Johnson, designed to last 15 years or more, is failing worldwide at unusually high rates after just a few years.
  3. ^ Farrell, Greg. "J&J Hip Failure Rate as High as 49 Percent, U.K. Doctors Say". Bloomberg. Retrieved 24 February 2012.
  4. ^ "Re: DuPay ASR Hip Cup (Cease and Desist Letter)". Kramer Levin Naftalis & Frankel LLP. April 1, 2010. Retrieved 12 November 2013.
  5. ^ a b Kalra, Aditya (7 September 2018). "J&J to work with India on compensation for recalled hip implants". Reuters. Retrieved 8 September 2018.
  6. ^ Hansen, David. "IN RE: DePUY ORTHOPAEDICS, INC., ASR HIP IMPLANT PRODUCTS LIABILITY LITIGATION" (PDF). Panel on Multidistrict Litigation.
  7. ^ Saunders, Joseph. "DePuy ASR Total Hip Replacement Settlement Update". Saunders & Walker, P.A. Retrieved 17 July 2014.

Further reading[edit]

External links[edit]